AgomAb Therapeutics NV reported €1.6M of revenue over the trailing twelve months, +32% on the year before. 7 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: €1.6M (to FY2025). Net income: −€63M, trailing twelve months to FY2025. Operating margin: −3684%, trailing twelve months to FY2025. EPS: −€143.22, trailing twelve months to FY2025.

AGMBAgomAb Therapeutics NV

Healthcare

$9.05

$8.1852 weeks$17.57

AGMB as reported

AgomAb Therapeutics NV reported €1.6M of revenue over the trailing twelve months, +32% on the year before. 7 reported series are charted on this page, each one as filed.

€1.6M

Revenue, trailing twelve months · to FY2025 · +32% against the twelve months before

Net income: −€63M
Net income · +35% year on year · trailing twelve months to FY2025
Operating margin: −3684%
Operating margin · trailing twelve months to FY2025
EPS: −€143.22
EPS · +34% year on year · trailing twelve months to FY2025

Details›

Every series Ryufin has for AGMB, trailing twelve months
Series	Latest	Year on year	As of
Revenue	€1.6M	+32%	FY2025
Net income	−€63M	+35%	FY2025
EPS	−€143.22	+34%	FY2025
Operating margin	−3684%	n/a	FY2025
Net margin	−3887%	n/a	FY2025
ROE	−48%	n/a	FY2025
ROA	−41%	n/a	FY2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.